Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03144206 · ClinicalTrials.gov registry record · Phase 4

Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study

A Phase 4 study of Sarcoma and Hyperbaric Oxygen Therapy, sponsored by Duke University.

Recruiting
Registry status
Phase 4
Development phase
20
Enrollment target
1
Study location

NCT03144206 is a Phase 4 study of Sarcoma and Hyperbaric Oxygen Therapy that is actively recruiting participants, run by Duke University. The registered enrollment target is 20 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03144206, a Phase 4 study of Sarcoma and Hyperbaric Oxygen Therapy, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
Phase 4
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

A parallel-group randomized pilot trial at a single institution (Duke University) on the effect of postoperative hyperbaric oxygen therapy on wound healing in patients with soft tissue sarcoma undergoing surgical resection with neo-adjuvant radiation therapy.. Participants will be allocated to either the treatment group (HBOT) or control (standard of care) by computer-generated randomization, stratified by tumor size (≤10cm and \>10cm). An unequal randomization of 2:1 will be utilized to provide experience prescribing HBOT to more patients.

Interventions

  • DRUG Hyperbaric oxygen

Study Locations (1)

North Carolina

  • Duke University - Durham

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2017-10-19
Est. Completion 2026-12-31
Phase Phase 4

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT03144206

The ClinicalTrials.gov registry entry for NCT03144206 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (98% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Hyperbaric oxygen is the first listed.

NCT03144206 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT03144206 about?

NCT03144206 is a clinical study titled "Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study". A parallel-group randomized pilot trial at a single institution (Duke University) on the effect of postoperative hyperbaric oxygen therapy on wound healing in patients with soft tissue sarcoma undergoing surgical resection with neo-adjuvant radiation therapy.. Participants will be allocated to eithe...

What is the current status of trial NCT03144206?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2017-10-19. Estimated completion is 2026-12-31.

What conditions does trial NCT03144206 study?

This clinical trial studies the following conditions: Sarcoma, Hyperbaric Oxygen Therapy.

What interventions are being tested in trial NCT03144206?

The interventions under investigation include: Hyperbaric oxygen (DRUG).

Who is sponsoring clinical trial NCT03144206?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03144206 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.